New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group

详细信息    查看全文

• 作者：Diego Cortinovis^a ; Vanesa Gregorc^b ; Maria Rita Migliorino^c ; Maria Ida Abate^a ; Anna Manzo^d ; Umberto Malapelle^e ; Alessandro Morabito^d ; ^{a.morabito@istitutotumori.na.it} ; ^{alessandromorabito1@virgilio.it} ; ^{alessandro.morabito@uosc.fondazionepascale.it} ; on behalf of The Italian Lung Cancer Working Group¹
• 关键词：Non squamous NSCLC ; Second line therapy ; Nintedanib ; Ramucirumab ; Nivolumab ; Pembrolizumab ; Atezolizumab ; Docetaxel ; Therapeutic strategy
• 刊名：Critical Reviews in Oncology/Hematology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：109
• 期：Complete
• 页码：35-41
• 全文大小：989 K
• 卷排序：109

文摘

Lung cancer is still considered a big killer among cancer diseases, due to high incidence and mortality rates. The newer frontiers of therapeutic development regard the discovery of oncogene driven tumours: however, the majority of NSCLC patients are wild type and they cannot be treated with targeted based agents. The recent positive results obtained with immunotherapy and with the combination of angiogenesis inhibitors and docetaxel, changed the therapeutic scenario of the second line therapy of non squamous NSCLC without actionable mutations. A major issue is currently the lack of predictive biomarkers that could help the oncologists in the choice of the best second-line treatment. Aim of this project was to define an optimal therapeutic pathway for patients with non-squamous NSCLC, through a working group of a large number of Italian lung cancer oncologists. Panellists have identified and discussed the more significant criteria in the second-line setting for a therapeutic decision between the combination of angiogenesis inhibitors plus chemotherapy or immunotherapy. Finally, they expressed their preference on each criterion, building a proposal of a decision-making tree for a second-line treatment of non-squamous NSCLC.